Feasibility of Allogeneic Hematopoietic Cell Transplantation in Elderly Patients with Myelodysplastic Syndrome
A recent study demonstrates that allogeneic hematopoietic cell transplantation is a feasible and effective treatment option for older adults with myelodysplastic syndrome, showing comparable survival outcomes to younger patients.
Recent research published in the European Journal of Haematology confirms that allogeneic hematopoietic cell transplantation (allo-HCT) can be successfully performed in older adults diagnosed with myelodysplastic syndrome (MDS). A multicenter retrospective study led by Dr. Fernando Barroso Duarte from Walter Cantídio University Hospital in Fortaleza, Brazil, evaluated outcomes for patients aged 65 and older compared to younger groups across 38 transplant centers in Latin America from 1988 to 2023.
The study included 441 patients, with 16% being 65 years or older. Results showed that five-year overall survival (OS) was 49.3% in the elderly group and 56.7% in younger patients, with progression-free survival (PFS) at 48.4% and 56.2%, respectively. The rates of relapse and nonrelapse mortality were 13.6% and 33.8%. Importantly, after adjusting for various factors, there were no significant differences in OS, relapse, or mortality between the age groups.
In patients aged 65 and above, factors such as high-risk disease scores, male sex, use of reduced-intensity conditioning, mobilized blood cell grafts, and prior treatments influenced outcomes. The study observed that elderly patients had a higher risk of disease relapse compared to younger patients but maintained comparable survival rates overall.
The authors concluded that allo-HCT remains a viable treatment option for elderly patients with MDS, challenging previous assumptions that age limits transplantation eligibility. They emphasized that careful patient selection and tailored conditioning regimens can optimize results, offering hope for improved management of MDS in older populations.
This study highlights the importance of not excluding older patients from potentially curative therapies like allo-HCT and encourages a more individualized approach based on overall health and disease risk factors.
Source: https://medicalxpress.com/news/2025-07-allogeneic-hct-feasible-older-patients.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Recent Research Highlights Predictors and Outcomes in Systemic Sclerosis
Recent research at EULAR 2025 highlights the importance of early diagnosis and key indicators for disease progression in systemic sclerosis, offering new insights for better patient management.
Combination of Chemotherapy and Natural Extract Castalin Enhances Cancer Treatment Effectiveness
New study shows that combining chemotherapy with natural extract castalin from chestnuts can boost cancer treatment effectiveness and reduce side effects, offering hope for improved therapies.
Increased Physical Activity Among NHS Active 10 App Users Demonstrated by Recent Study
A recent study demonstrates that users of the NHS Active 10 walking app increase their brisk and overall walking activity, with benefits lasting over two years, indicating its potential for promoting public health.
U.S. Reports Over 1,000 Measles Cases Across 11 States Amid Ongoing Outbreaks
The United States reports over 1,000 measles cases across 11 states, driven by outbreaks in Texas and other regions. Vaccination remains crucial to control the resurgence of this contagious disease.